First-in-human imaging with [ 89 Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.

Salomon TendlerMark P DunphyMatthew AgeeJoseph O'DonoghueRania G AlyNoura J ChoudhuryAdam KesnerAssen KirovAudrey MauguenMarina K BaineHeiko SchoderWolfgang A WeberNatasha RekhtmanSerge K LyashchenkoLisa BodeiMichael J MorrisJason S LewisCharles M RudinJohn T Poirier

Published in: medRxiv : the preprint server for health sciences (2024)

Supported by NIH R01CA213448 (JTP), R35 CA263816 (CMR), U24 CA213274 (CMR), R35 CA232130 (JSL), and a Prostate Cancer Foundation TACTICAL Award (JSL), Scannell foundation. The Radiochemistry and Molecular Imaging Probes Core Facility is supported by NIH P30 CA08748.

Keyphrases

prostate cancer
high grade
neuroendocrine tumors
protein kinase
radical prostatectomy
small molecule
pet imaging
low grade
fluorescence imaging
single molecule